Innovations In ADC Technologies

Antibody-Drug Conjugates (ADCs) have held promise as a targeted treatment for cancers that combines high efficacy with tolerability. While this modality failed to achieve success in clinical trials for many years, there has been a lot of activity in the ADC market in the past 12-18 months in terms of licensing deals, acquisitions, and investments. It’s likely no coincidence that this increased interest coincides with an increase in approvals over the past two years.

Hear Mike Riley, Catalent Biologics, Regional President, North America, discuss the drivers behind the recent successes in the clinic, current challenges with development and manufacturing, and what the future might hold for the ADC industry.